Preventing the production of IL-1β during P. aeruginosa keratitis by silencing the gene for ﻿the inflammasome NLRC4 [18], inhibiting caspase-1 production (either using gene knockout mice or antibodies) [19,72], or administering IL-1Ra (a natural inhibitor of IL-1β) [21] reduces the clinical pathology of keratitis. This evidence concerns the gene NLRC4 and keratitis.